Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Prevention of Delayed Graft Function
NCT01919346Phase 2Terminated
- Start
- Aug 2013
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in delayed graft function (DGF). Started Aug 2013; status: terminated.
02
Drugs
eculizumab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT01919346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01919346.